

Long-term treatment with dimethyl fumarate for plaque psoriasis in routine practice: good overall effectiveness and positive effect on impactful areas

Matthias Augustin¹, Lilla Landeck², Sebastian Diemert³, Khusru Asadullah⁴, Urte Hammann⁵, Konstantin Ertner⁶, Ina Hadshiew⁷

¹ Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany

² Ernst von Bergmann General Hospital, Potsdam, Germany

³ Almirall Hermal GmbH, Reinbek, Germany

⁴ Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany, and Hautarztpraxis Prof. Dr. med. K. Asadullah, Potsdam, Germany

⁵ Hautarztpraxis Dr. U. Hammann, Stade, Germany

⁶ Hautarztpraxis Dr. K. Ertner, Nürnberg, Germany

⁷ Derma-Köln, Cologne, Germany

Corresponding author:

Prof. Dr. med. Matthias Augustin

Director, Institute for Health Services Research in Dermatology and Nursing (IVDP)

University Medical Center Hamburg-Eppendorf (UKE)


Martinistr. 52, 20246 Hamburg, Germany

Phone: +49 40 7410 55428

E-mail: m.augustin@uke.de

SUPPLEMENTARY MATERIAL


Figure S1. Change in BSA from baseline to week 52



$p < 0.001$ vs. baseline for any visit and OC and LOCF, respectively, Wilcoxon signed-rank test. Abbreviations: BSA – body surface area, LOCF – last observation carried forward, OC – observed cases


Figure S2.

a – Change of nail psoriasis from baseline severity




LOCF, n=481. Abbreviations: LOCF – last observation carried forward, PGA – Physician Global Assessment

b – Improvement of palmoplantar psoriasis from baseline severity




LOCF, n=481. Abbreviations: LOCF – last observation carried forward, PP-PGA – palmoplantar Physician Global Assessment

Figure S3. Proportion of patients with no or only mild pruritus



n = 660 (OC baseline), n = 251 (OC week 52), n = 473 (LOCF); p < 0,001 vs. baseline, using OC and LOCF, McNemar test. Abbreviations: LOCF – last observation carried forward, NRS – numerical rating scale, OC – observed cases

Figure S4. Main reason for therapy discontinuation



n = 299, 332 reasons for early treatment termination (more than 1 reason was possible per patient)